Compare PHR & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHR | LTGO |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.3M | 924.9M |
| IPO Year | 2019 | 2026 |
| Metric | PHR | LTGO |
|---|---|---|
| Price | $12.58 | $13.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 4 |
| Target Price | $13.93 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 633.2K | 214.8K |
| Earning Date | 12-07-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.92 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $480,591,000.00 | N/A |
| Revenue This Year | $7.32 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | $155.56 | ★ N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $7.77 | $13.50 |
| 52 Week High | $23.31 | $25.93 |
| Indicator | PHR | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 69.00 | 36.77 |
| Support Level | $11.38 | $13.50 |
| Resistance Level | $12.70 | $17.67 |
| Average True Range (ATR) | 0.47 | 1.39 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 89.79 | 4.25 |
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.